veloxa vet 525 mg / 504 mg / 175 mg purutabletti
lavet pharmaceuticals ltd. - febantel, praziquantel, pyrantel embonate - purutabletti - 525 mg / 504 mg / 175 mg - pratsikvanteeli
ursoferran 200 mg/ml injektioneste, liuos
serumwerk bernburg ag - gleptoferron - injektioneste, liuos - 200 mg/ml - rauta
anthelmin vet 50 mg / 144 mg / 150 mg tabletti
krka, d.d., novo mesto - pyrantel embonate, febantel, praziquantel - tabletti - 50 mg / 144 mg / 150 mg - febanteli
anthelmin vet 175 mg / 504 mg / 525 mg tabletti
krka, d.d., novo mesto - pyrantel embonate, febantel, praziquantel - tabletti - 175 mg / 504 mg / 525 mg - febanteli
euthoxin vet 500 mg/ml injektioneste, liuos
chanelle pharmaceuticals manufacturing limited - pentobarbital sodium - injektioneste, liuos - 500 mg/ml - pentobarbitaali
paracetamol baxter viaflo 10 mg/ml infuusioneste, liuos
baxter holding b.v. - paracetamol - infuusioneste, liuos - 10 mg/ml - parasetamoli
paracetamol baxter 10 mg/ml infuusioneste, liuos
baxter holding b.v. - paracetamol - infuusioneste, liuos - 10 mg/ml - parasetamoli
arsenic trioxide medac
medac gesellschaft für klinische spezialpräparate mbh - arseenitrioksidi - leukemia, promyelocytic, akuutti - antineoplastiset aineet - arsenic trioxide medac is indicated for induction of remission, and consolidation in adult patients with:newly diagnosed low-to-intermediate risk acute promyelocytic leukaemia (apl) (white blood cell count, ≤ 10 x 10³/μl) in combination with all-trans-retinoic acid (atra)relapsed/refractory apl (previous treatment should have included a retinoid and chemotherapy) characterised by the presence of the t(15;17) translocation and/or the presence of the pro-myelocytic leukaemia/retinoic-acid-receptor-alpha (pml/rarα) gene. vastausprosentti muita akuutin myelooisen leukemian alatyyppien mukaan arseenitrioksidi ei ole tutkittu.